Equity Opportunity
Open to Investors
C-Reveal Therapeutics

C-Reveal Therapeutics

Our immune system relies on distinct markers, called tumor antigens, to recognize what is and is not cancer. However, many tumors have a low antigen load and are thus largely hidden from the immune system. Because of this, new therapies that enlist the immune system to fight cancer (e.g., drugs such as OPDIVO® and KEYTRUDA®) are less effective than they could be, working well in only about 10% of patients.

Our company has identified 2 key cancer-specific enzymes that, when inhibited, reveal hidden tumors to the immune system. C-Reveal plans to develop inhibitors for these enzymes, whi...

Min investment
Amount raised
Days Left
Pembroke, MA

CrowdLustro Research Report

Security Type
Common Stock
Common stock is a security that represents ownership in a corporation.
December 18, 2020
February 17, 2021
Valuation Cap

Use of Proceeds

  • R&D Pilot phase (Evotec)
  • R&D HTS (Evotec)
  • MGH Patent
  • New Patents
  • CEO/Legal
  • CSO
  • Outsourced CFO
  • Marketing & BD Expenses
  • Operating Expenses (IT)
  • Intermediary fees


Thomas Haag, Ph.D, J.D.
Dr. Haag is a biotechnology IP lawyer, investor and entrepreneur. He previously served as co-founder and acting CEO of PhosImmune, acquired by Agenus, Inc. (NASDAQ: AGEN) for $45 million. He is the founder of Haag Life Sciences Law and is a Managing Partner of Linden Lake Venture Capital. Dr. Haag has a 20-year background in biotech IP and served as partner and Co-chair of Seyfarth Shaw LLP’s Life Sciences IP Practice.

Mark Cobbold, M.D., Ph.D.
Scientific Co-founder
Dr. Cobbold currently serves as the V.P. of Oncology Early Discovery at AstraZeneca. He previously co-founded Gritstone Oncology, which IPOed with a $100 million market cap. He also served as Scientific Co-Founder at Serascience, which was sold to Abingdon Health, PhosImmune Inc. (acquired by Agenus) and Revitope Oncology.

Keith Flaherty, M.D.
Scientific Co-founder
Dr. Flaherty previously co-founded Loxo Oncology, which was acquired by Eli Lilly for $8 billion. Dr. Flaherty currently serves as the Director of The Termeer Center for Targeted Therapies, Director of Clinical Research, and Richard Saltonstall Endowed Chair in Oncology at Mass General Hospital Cancer Center. He is also a Professor of Medicine at Harvard University and leads the Developmental Therapeutics research program at the Dana-Farber/Harvard Cancer Center.

Cyril Benes, Ph.D.
Scientific Co-founder
Dr. Benes currently serves as the Director of Oncology Bioinformatics at the Genomics Institute of the Novartis Research Foundation. He was previously a professor at Harvard Medical School and was the former Head of the Center for Molecular Therapeutics at the Massachusetts General Hospital Cancer Center.

Deal Structure

Price per Share: $10.00

Research Reports

No reports have been submitted

Become Reporter

Key Deal Facts

Proprietary technology developed at Massachusetts General Hospital and Harvard University
Founded by Harvard Scientists
Multiple previous exits in excess of $8 billion
$141 billion oncology market expected to reach more than $390 billion by 2027